Eton Pharmaceuticals Stock Forecast, Price & News

-0.29 (-4.63 %)
(As of 06/18/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume782,734 shs
Average Volume382,158 shs
Market Capitalization$146.56 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ETON News and Ratings via Email

Sign-up to receive the latest news and ratings for Eton Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Eton Pharmaceuticals logo

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. It also develops ET-105, a lamotrigine for oral suspension; DS-300, a cysteine injection; DS-100, a dehydrated alcohol injection; ET-104, a zonisamide oral suspension; ET-101, a topiramate oral suspension; and ET-203, an ephedrine ready-to-use injection. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.47 out of 5 stars

Medical Sector

627th out of 2,097 stocks

Pharmaceutical Preparations Industry

303rd out of 831 stocks

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Eton Pharmaceuticals (NASDAQ:ETON) Frequently Asked Questions

Is Eton Pharmaceuticals a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eton Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Eton Pharmaceuticals stock.
View analyst ratings for Eton Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Eton Pharmaceuticals?

Wall Street analysts have given Eton Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Eton Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Eton Pharmaceuticals' next earnings date?

Eton Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 11th 2021.
View our earnings forecast for Eton Pharmaceuticals

How were Eton Pharmaceuticals' earnings last quarter?

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) posted its quarterly earnings results on Thursday, May, 13th. The company reported $0.19 EPS for the quarter, meeting the consensus estimate of $0.19.
View Eton Pharmaceuticals' earnings history

How has Eton Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

Eton Pharmaceuticals' stock was trading at $4.20 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ETON stock has increased by 42.4% and is now trading at $5.98.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ETON?

2 brokerages have issued twelve-month price objectives for Eton Pharmaceuticals' shares. Their forecasts range from $11.00 to $14.00. On average, they anticipate Eton Pharmaceuticals' stock price to reach $12.50 in the next year. This suggests a possible upside of 109.0% from the stock's current price.
View analysts' price targets for Eton Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Eton Pharmaceuticals' key executives?

Eton Pharmaceuticals' management team includes the following people:
  • Mr. Sean E. Brynjelsen, Pres, CEO & Director (Age 49, Pay $705.93k)
  • Mr. W. Wilson Troutman CPA, CFO, Treasurer & Sec. (Age 67, Pay $396.48k)
  • Mr. Paul Stickler, Sr. VP of Sales & Marketing
  • Ms. Bharathi Devarakonda, Sr. VP of Regulatory Affairs & Product Devel.
  • Ms. Ingrid Hoos, Sr. VP of Regulatory Affairs
  • Mr. Scott Grossenbach, VP of Sales & Marketing
  • Mr. David Krempa CFA, VP of Bus. Devel.

Who are some of Eton Pharmaceuticals' key competitors?

What other stocks do shareholders of Eton Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eton Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Amarin (AMRN), Myovant Sciences (MYOV), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Vaxart (VXRT), CymaBay Therapeutics (CBAY), Fulcrum Therapeutics (FULC) and Moderna (MRNA).

When did Eton Pharmaceuticals IPO?

(ETON) raised $22 million in an IPO on Wednesday, November 14th 2018. The company issued 3,600,000 shares at $6.00 per share. National Securities Corporation served as the underwriter for the IPO.

What is Eton Pharmaceuticals' stock symbol?

Eton Pharmaceuticals trades on the NASDAQ under the ticker symbol "ETON."

Who are Eton Pharmaceuticals' major shareholders?

Eton Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (4.44%), AWM Investment Company Inc. (3.67%), Geode Capital Management LLC (1.08%), Northern Trust Corp (0.73%), Westside Investment Management Inc. (0.35%) and Sei Investments Co. (0.30%). Company insiders that own Eton Pharmaceuticals stock include Charles J Casamento, Harrow Health, Inc, Opaleye Management Inc and Sean Brynjelsen.
View institutional ownership trends for Eton Pharmaceuticals

Which institutional investors are selling Eton Pharmaceuticals stock?

ETON stock was sold by a variety of institutional investors in the last quarter, including MML Investors Services LLC, AWM Investment Company Inc., JPMorgan Chase & Co., Northern Trust Corp, Sei Investments Co., Diametric Capital LP, and Nuveen Asset Management LLC. Company insiders that have sold Eton Pharmaceuticals company stock in the last year include Harrow Health, Inc, and Opaleye Management Inc.
View insider buying and selling activity for Eton Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Eton Pharmaceuticals stock?

ETON stock was acquired by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, GSA Capital Partners LLP, BlackRock Inc., Barclays PLC, and Westside Investment Management Inc.. Company insiders that have bought Eton Pharmaceuticals stock in the last two years include Charles J Casamento, Opaleye Management Inc, and Sean Brynjelsen.
View insider buying and selling activity for Eton Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Eton Pharmaceuticals?

Shares of ETON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Eton Pharmaceuticals' stock price today?

One share of ETON stock can currently be purchased for approximately $5.98.

How much money does Eton Pharmaceuticals make?

Eton Pharmaceuticals has a market capitalization of $146.56 million and generates $40,000.00 in revenue each year. The company earns $-27,970,000.00 in net income (profit) each year or ($1.33) on an earnings per share basis.

How many employees does Eton Pharmaceuticals have?

Eton Pharmaceuticals employs 16 workers across the globe.

What is Eton Pharmaceuticals' official website?

The official website for Eton Pharmaceuticals is

Where are Eton Pharmaceuticals' headquarters?

Eton Pharmaceuticals is headquartered at 21925 W. FIELD PARKWAY SUITE 235, DEER PARK IL, 60010.

How can I contact Eton Pharmaceuticals?

Eton Pharmaceuticals' mailing address is 21925 W. FIELD PARKWAY SUITE 235, DEER PARK IL, 60010. The company can be reached via phone at 847-787-7361 or via email at [email protected]

This page was last updated on 6/20/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.